Clinical trial details

A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)

Identifier

MK-6482-022

Sponsor

MERCK SHARP & DOHME CORP

Principal Investigator

CRISTINA SUAREZ RODRIGUEZ

Service

Oncology

Study details

Tumor type: RENAL
Stage: Early/Locally advanced
Main Investigational Agent : Targeted therapy
Phase: III
Randomization: Randomized

Molecular details

Biomarker: Not applicable
Biomarker criteria: Not applicable
Prescreening: Not applicable
Additional study population requirements: Not applicable

Drug details

Arm A: Belzutifan and Pembrolizumab
Arm B: Placebo and Pembrolizumab

Links

Clinical Trials GOV (NCT identifier): NCT05239728
EU Clinical Trials Register (eudraCT Identifier): 2021-003436-92